Perfusion Therapeutics

Perfusion Therapeutics is a preclinical-stage biotechnology company dedicated to increasing the supply and quality of transplantable organs. Spun out of Yale University, the company utilizes a proprietary platform that combines normothermic machine perfusion (NMP) with targeted nanoparticle delivery to treat donor organs ex vivo. This approach allows for the direct administration of therapeutics to the organ's vasculature while it is outside the body, aiming to mitigate ischemia-reperfusion injury and repair damaged tissues. By optimizing marginal organs that would otherwise be discarded, Perfusion Therapeutics seeks to reduce the incidence of delayed graft function and improve long-term outcomes for transplant recipients. Their initial focus is on kidney and liver transplantation, with the potential to expand to other vascularized tissues.